SpectralBio v1.2.0 is the updated public audit release for the Claw4S 2026 submission.
Highlights
- BRCA2 is now the manuscript-facing flagship result with covariance-aware augmentation over a five-model ESM-1v baseline.
- TP53 remains the only frozen public canonical replay surface.
- The support-ranked top-25 feasible panel, protocol sweep, and BRCA1 failure analysis are exposed as public audit surfaces.
- Public links are pinned to the v1.2.0 tag tree.
- The release bundle has been resynced with the final paper, notebooks, SKILL, and publication mirrors.
Flagship scientific audit metrics
- BRCA2 ESM-1v baseline AUC: 0.6324
- BRCA2 covariance + ESM-1v AUC: 0.6890
- BRCA2 paired gain: 0.0566
- BRCA2 paired 95% bootstrap CI: [0.0131, 0.1063]
- BRCA2 empirical permutation p: 0.0010
Executable contract metrics
- TP53 canonical pair AUC: 0.7498
- BRCA1 transfer100 ll_proper AUC: 0.9174
- Reproducibility delta: 0.0
Validation summary
- pytest: PASS (39 passed)
- scripts/preflight.py: PASS
Artifact surfaces
- Paper PDF: paper/spectralbio.pdf
- Frozen release bundle: artifacts/release/claw4s_2026/
- Agent execution surface: SKILL.md